BridgeMD
New treatment option for Bone Sarcoma
Official title In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma
ClinicalTrials.gov ID: NCT02811523
What this study is testing
What is Doxorubicin?
Doxorubicin is an investigational medicine, being studied as a potential treatment for bone sarcoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Sarcoma which has spread to the lungs is most often treated with surgery. Even with surgery, most patients will not be cured and will die from their disease, probably because of small cancer cells that are present in the lungs at the time of surgery, but cannot be seen or detected.
- Phase 1: an early, usually small safety study
- Time commitment: about 2 years
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 0 to 64
You may be able to join if
- Diagnosis of Soft Tissue or Osteogenic Sarcoma
- Presence of bilateral pulmonary metastases
- 3 or more lung lesions in total
- Age less than 65 years
- ECOG 0-2
You likely can't join if
- Patient has previously received more than 450 mg of doxorubicin
- Left Ventricular Ejection Fraction \<50%
- History of significant pulmonary disease or pneumonitis
- Pregnant or lactating females
- Age 65 years or older, or less than 18 years
- Inability to understand the informed consent process
See the full eligibility criteria
- Diagnosis of Soft Tissue or Osteogenic Sarcoma
- Presence of bilateral pulmonary metastases
- 3 or more lung lesions in total
- Age less than 65 years
- ECOG 0-2
- Absence of extra-pulmonary disease
- Contralateral disease amenable to surgery or radiation
- All lung lesions in the lung to be treated with IVLP can be resected with wedge or segmental resections (non-IVLP treated lung will be treated with radiation or surgery 4-12 weeks prior to IVLP)
- Patient has previously received more than 450 mg of doxorubicin
- Left Ventricular Ejection Fraction \<50%
- History of significant pulmonary disease or pneumonitis
- Pregnant or lactating females
- Age 65 years or older, or less than 18 years
- Inability to understand the informed consent process
- Hypersenstivity to doxorubicin
- Current participation in another therapeutic clinical trial
- Previous lung metastatectomy
The study team makes the final eligibility decision.
Where it's taking place
- Toronto, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 2 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 0 years to 64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Toronto, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.